Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 319

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm

Open access
Haberer, Jessica E., Bangsberg, David R., Baeten, Jared M., Curran, Kathryn, Koechlin, Florence, Amico, K. Rivet, Anderson, Peter, Mugo, Nelly, Venter, Francois, Goicochea, Pedro, Caceres, Carlos, O’Reilly, Kevin·2015·AIDS

Abstract

Introduction To date, six clinical trials have explored the efficacy of pre-exposure prophylaxis (PrEP) against HIV infection using oral tenofovir and/or emtricitabine/tenofovir [1–6]. Efficacy ranged from 0 to 75% [7], the variation of which can largely be explained by differences in PrEP adherence [8]. Efficacy data directly correlate with the objective adherence measures in those studies, and efficacy estimates were between 90 and 100% when adherence was consistently high [2,9,10]. PrEP is clearly efficacious when taken as prescribed. Pre-exposure prophylaxis adherence is, however, complex and should be understood within the context of variable risk for HIV infection and use of other HIV-prevention methods. Different levels of adherence may be needed in different populations to achieve HIV prevention, and the optimal methods for achieving the necessary adherence for both individual and public health benefits are unknown. In moving beyond clinical trials toward demonstration projects (i.e. studies of PrEP delivery methods) and broader implementation in clinical care, guidance for PrEP use must consider these questions to determine if PrEP-based HIV-prevention programs are successful at both the individual and public health level. In this article, we propose a new paradigm for understanding and measuring PrEP adherence, termed prevention-effective adherence, which incorporates dynamic HIV-acquisition risk behaviors and the use of HIV-alternative prevention strategies. We focus on sexual transmission of HIV, as the role of PrEP in preventing HIV transmission via injection drug use is less well understood. We discuss the need for daily PrEP use only during periods of risk for HIV exposure, describe key issues for measuring and understanding relevant behaviors, review lessons from another health-prevention field (i.e. family planning), and provide guidance for prevention-effective PrEP use. Moreover, we challenge emerging calls for sustained, near-perfect PrEP adherence, regardless of risk exposure, and offer a more practical and public health-focused vision for this prevention intervention. Understanding pre-exposure prophylaxis adherence Sustained lifelong high adherence: the paradigm for antiretroviral therapy The adherence message for antiretroviral therapy (ART) of HIV infection is simple: viral suppression and improved health require indefinite, consistently high adherence following ART initiation [11]. Whereas early regimens required at least 95% adherence [12], contemporary regimens reliably suppress viral replication at somewhat lower adherence levels (e.g. 80%) [13,14], depending on adherence patterns and prior duration of viral suppression [15,16]. Nevertheless, lifelong sustained adherence is required to stop disease progression. While scheduled intermittent dosing of ART (e.g. planned drug holidays) was suggested to ease the adherence burden, studies of prescribed intermittent ART and unplanned missed doses showed increased rates of viral rebound and worse clinical outcomes [17,18]. Sustained high adherence for the duration of pre-exposure prophylaxis clinical trials High levels of sustained adherence are also required for the evaluation of efficacy and safety of potential PrEP agents. Thus, in placebo-controlled, randomized clinical trials, one could argue for selecting participants who are motivated to adhere, as well as providing intense adherence support to maintain consistently high adherence regardless of dynamic risk behaviors. This scenario, however, does not generalize to open-label use and uptake of PrEP that is now known to be effective. Prevention-effective adherence: a novel paradigm Several differences between ART and PrEP (as used outside of clinical trials) are noted in Table 1, and the type of adherence needed for each setting is presented in Fig. 1. The message for PrEP adherence is not simply 100% adherence for life or the duration of a research study. Because an individual's risk for HIV acquisition changes over time and alternative prevention strategies may be used, the indication for PrEP also changes over time. PrEP use, for example, may not be indicated if sexual activity is restricted to a monogamous relationship with a known HIV-negative partner without other risk exposures, or if another effective HIV-prevention tool (e.g. condoms) is consistently used. Perfect PrEP adherence in the absence of risk confers cost, side effects, and toxicity, but no benefit. Consistently high adherence during periods of exposure, however, is critical when PrEP is being used for effective HIV prevention.Table 1: Differences between antiretroviral therapy and pre-exposure prophylaxis as used outside of clinical trials.Fig. 1: Adherence success by adherence paradigm.The paradigm of consistently high adherence for all individuals applies to ART and PrEP in clinical trials (panel a). The prevention-effective paradigm applies to PrEP in demonstration projects and wider implementation (panel b).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/qad.0000000000000647

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 319

Metadata

Authors
Haberer, J. E., Bangsberg, D. R., Baeten, J. M., Curran, K., Koechlin, F., Amico, K. R., Anderson, P., Mugo, N., Venter, F., Goicochea, P., Caceres, C., & O’Reilly, K.
Venue
AIDS
Published
2015-07-17
Volume
29
Issue
11
Pages
1277-1285
ISSN
0269-9370 (ISSN-L)
OpenAlex
W1979495409
Cited by
319
References
40
FWCI
13.01
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. https://app.cochat.ai/papers/10.1097/qad.0000000000000647
The paper
Haberer, J. E., Bangsberg, D. R., Baeten, J. M., Curran, K., Koechlin, F., Amico, K. R., Anderson, P., Mugo, N., Venter, F., Goicochea, P., Caceres, C., & O’Reilly, K. (2015). Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. AIDS. https://doi.org/10.1097/qad.0000000000000647

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.